1334513-02-8

• 常用中文名：N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯
• 常用英文名：N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine1-Methylethylester
• CAS号：1334513-02-8
• 分子式：C₁₈H₁₇F₅NO₅P
• 分子量：453.297
• 相关类别： 医药中间体 原料药中间体
• 发布时间：2018-12-31 17:43:57
• 更新时间：2026-07-07 19:51:12
• (S) 异丙基2-(((S)-(全氟苯氧基)(苯氧基磷酰基)氨基)丙酸酯是丙氨酸衍生物[1]。

名称

• 中文名: 索氟布韦中间体
• 英文名: propan-2-yl (2S)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate
• 中文别名: 化合物 (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE; SOFSOSBUVIR中间体; (S)-2-(((S)-全氟苯氧基)(苯氧基)磷酰基)氨基)丙酸异丙酯; 索非布韦中间体-9; N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧磷酰基]-L-丙氨酸 1-甲乙基酯; 索菲布韦中间体4; 索弗布韦中间体SFC; 索菲布韦中间体5/N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯; 索非司布韦国际药典杂质G; 索福斯布韦杂质T; 索非布韦标准品-SS; N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯1334-8; N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯(五氟侧链); N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯 索非布韦中间体-9; N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯/N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester; (2S)-2-[[(S)-(全氟苯氧基)(苯氧基)磷酰基]氨基]丙酸异丙酯; 索非布韦中间体2; I-[(S)-(2,3,4,5,6-五氟苯氧基) 苯氧基磷酰基]-L-丙氨酸异丙酯; 索非布韦中间体5; 索非布韦IMP-75; 索氟布韦 中间体 SF-1.2; 库存产品,索非布韦的中间体1334-8; N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯(索菲布韦中间体4); 索非布韦杂质15; 索非布韦原料2; 索非布韦中间体,索氟布韦中间体
• 英文别名: 6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester; Sofibuvir intermediate 1; Sofosbuvir side chain N-1; Propan-2-yl N-[(S)-(pentafluorophenoxy)(phenoxy) phosphoryl]-L-alaninate; (S)-isopropyl 2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate; L-Alanine, N-[(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-, 1-methylethyl ester; 2'-Defluro-2'-hydroxy 2'-i-Sofosbuvir; (S)-2-[(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester; (R)-Sofosbuvir Pentafluorophenoxy AnalogueQ: What is (R)-Sofosbuvir Pentafluorophenoxy Analogue Q: What is the CAS Number of (R)-Sofosbuvir Pentafluorophenoxy Analogue Q: What is the storage condition of (R)-Sofosbuvir Pentafluorophenoxy Analogue Q: What e the applications of (R)-Sofosbuvir Pentafluorophenoxy Analogue; N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester (SIDE CHAIN); N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl este; N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester; ((2R,3R,4S,5R)-3-(benzoyloxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate; (2S)-isopropyl 2-(((perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate; Sofosbuvir-003-SS; N-[(S)-(2,3,4,5, 6-pentafluorophenoxy) phenoxyphosphoacyl] -L-alanine isopropyl ester; Isopropyl N-[(pentafluorophenoxy)(phenoxy)phosphoryl]-L-alaninate; N-[ -(2,3,4,5,6-pentafluoro phenoxy)phenoxy phosphinyl]-L-alanine-1-methyl ethyl ester; L-Alanine, N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-, 1-methylethyl ester; N-[(S)-(2,3,4,5, 6-pentafluorophenoxy) phenoxyphosphoryl] -L-alanine isopropyl ester; 1. (S)-isopropyl2-(((S)-(perfluorophenoxy)(phenoxy)phosphoryl); 2(S)-[((S)-2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester; Sofosbuvir InterMediates4; Sofosbuvir imp-75; N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alaninel-Methylethyl ester; (R)-Sofosbuvir Pentafluorophenoxy Analogue; 8 N-[(S)-(2,3,4,5,6 pentafluorophenoxy) phenoxyphosphinyl]-L-alanine 1-Methylethyl ester; propan-2-yl (2S)-2-{[(S)-pentafluorophenoxy(phenoxy)phosphoryl]amino}propanoate; SF-1.2; Sofosbuvir InterMediates; SofosBuvir Impurity 15; N-[(S)-(2,3,4,5,6-Pentafluorophenoxy)phenoxyphosphinyl]-L-alanineisopropylester(SF-1); Isopropyl (2S)-2-[[(S)-(Perfluorophenoxy)(phenoxy)phosphoryl]amino]propionate; N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester ISO 9001：2015 REACH; L-alanien,N-[(S)-(2,3,4,5,6-Pentafluorophenoxy)-phenoxy-phosphinyl]-1-Methylethylester; N-[(S)-(2,3,4,5,6-pentafluorophenoxy) phenoxyphosphatidyl ]- L- alanine isopropyl ester; ATP-FTP-phoph; (2S)-Isopropyl-2-((perfluorophexyl) (phenoxy)phosphorylamino Propanoate; Sofosbuvir Intermediate 5; isopropyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate; N - [(S) - (2,3,4,5,6-neneneba pentafluorophenyl oxy) phenoxyphosphoryl] - L-alanine isopropyl ester; Isopropyl N-[(S)-(pentafluorophenoxy)(phenoxy)phosphoryl]-L-alaninate; Isopropyl N-[(pentafluorophenoxy)(phenoxy)phosphoryl]-L-alan; propan-2-yl(2S)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate; isopropyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanite

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 442.6±55.0 °C at 760 mmHg
• 分子式: C₁₈H₁₇F₅NO₅P
• 分子量: 453.297
• 闪点: 221.5±31.5 °C
• 精确质量: 453.076447
• PSA: 83.67000
• LogP: 4.41
• 外观性状: 灰白色 粉末
• 蒸汽压: 0.0±1.1 mmHg at 25°C
• 折射率: 1.497
• 储存条件: 室温，干燥，密封

生物活性

• 描述: (S) 异丙基2-(((S)-(全氟苯氧基)(苯氧基磷酰基)氨基)丙酸酯是丙氨酸衍生物[1]。
• 相关类别:
  研究领域 >> 其他
  信号通路 >> 其他 >> 其他
• 体外研究: 氨基酸和氨基酸衍生物已被商业化用作能量补充剂。它们影响合成代谢激素的分泌、运动期间的燃料供应、压力相关任务期间的精神表现,并防止运动引起的肌肉损伤。它们被认为是有益的能生膳食物质[1]。
• 参考文献:

  [1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1054.

安全

• 危害码 (欧洲): Xi

合成路线

17788-07-7 39613-92-8 ~% 1334513-02-8 1337529-56-2

文献：WO2010/135569 A1, ; Page/Page column 52-53 ; WO 2010/135569 A1

261909-49-3 771-61-9 ~% 1334513-02-8 1337529-56-2

文献：WO2012/142085 A1, ; Page/Page column 74-75 ;

771-61-9 770-12-7 39613-92-8 ~34% 1334513-02-8

文献：Journal of Organic Chemistry, , vol. 76, # 20 p. 8311 - 8319

上下游产品

上游产品  5
17788-07-7 39613-92-8 261909-49-3 771-61-9
770-12-7
下游产品  1
1190307-88-0